Mar 24, 2021

Featuring an interview with Dr Manmeet Ahluwalia on the following topics:

• Management of CNS metastases in patients with non-small cell lung cancer (NSCLC) (0:00)
• Case: A woman in her mid-40s with NSCLC and an EGFR mutation who presented with multiple brain metastases receives stereotactic radiosurgery (SRS) and osimertinib on a clinical trial (29:05)
• Case: A woman in her early 50s with metastatic NSCLC with an ALK rearrangement has a complete response in the brain after receiving alectinib and SRS (29:56)
• Case: A man in his early 60s with Stage IV poorly differentiated adenocarcinoma and 100% PD-L1 expression receives SRS and immunotherapy (30:50)
• Evolving research and treatment for patients with NSCLC and brain metastases (31:54)
• Therapeutic approach for patients with NSCLC with targetable mutations and brain metastases (36:15)
• Efficacy of SRS with targeted therapy or immunotherapy in patients with CNS metastases (38:39)
• Benefits and risks with the combination of radiation therapy and immunotherapy or targeted therapy (44:57)
• Activity and tolerability of nivolumab with ipilimumab in patients with metastatic NSCLC and CNS involvement (51:20)
• CNS penetration of targeted therapies; safety of immunotherapy or targeted therapy during radiation therapy (54:48)
• Role of tumor treating fields in the treatment of brain metastases and glioblastoma multiforme (58:59)
• Novel agents and approaches under investigation for patients with NSCLC and brain metastases (1:03:46)

CME information and select publications